201 related articles for article (PubMed ID: 15546090)
1. Oral miltefosine for leishmaniasis in immunocompromised patients: compassionate use in 39 patients with HIV infection.
Sindermann H; Engel KR; Fischer C; Bommer W;
Clin Infect Dis; 2004 Nov; 39(10):1520-3. PubMed ID: 15546090
[TBL] [Abstract][Full Text] [Related]
2. Miltefosine for visceral leishmaniasis relapse treatment and secondary prophylaxis in HIV-infected patients.
Marques N; Sá R; Coelho F; Oliveira J; Saraiva Da Cunha J; Meliço-Silvestre A
Scand J Infect Dis; 2008; 40(6-7):523-6. PubMed ID: 18584541
[TBL] [Abstract][Full Text] [Related]
3. Successful treatment with miltefosine of disseminated cutaneous leishmaniasis in a severely immunocompromised patient infected with HIV-1.
Schraner C; Hasse B; Hasse U; Baumann D; Faeh A; Burg G; Grimm F; Mathis A; Weber R; Günthard HF
Clin Infect Dis; 2005 Jun; 40(12):e120-4. PubMed ID: 15909255
[TBL] [Abstract][Full Text] [Related]
4. Miltefosine: oral treatment of leishmaniasis.
Soto J; Soto P
Expert Rev Anti Infect Ther; 2006 Apr; 4(2):177-85. PubMed ID: 16597200
[TBL] [Abstract][Full Text] [Related]
5. A comparison of miltefosine and sodium stibogluconate for treatment of visceral leishmaniasis in an Ethiopian population with high prevalence of HIV infection.
Ritmeijer K; Dejenie A; Assefa Y; Hundie TB; Mesure J; Boots G; den Boer M; Davidson RN
Clin Infect Dis; 2006 Aug; 43(3):357-64. PubMed ID: 16804852
[TBL] [Abstract][Full Text] [Related]
6. Cure of antimony-unresponsive Indian post-kala-azar dermal leishmaniasis with oral miltefosine.
Sundar S; Kumar K; Chakravarty J; Agrawal D; Agrawal S; Chhabra A; Singh V
Trans R Soc Trop Med Hyg; 2006 Jul; 100(7):698-700. PubMed ID: 16325873
[TBL] [Abstract][Full Text] [Related]
7. Short-course of oral miltefosine for treatment of visceral leishmaniasis.
Sundar S; Makharia A; More DK; Agrawal G; Voss A; Fischer C; Bachmann P; Murray HW
Clin Infect Dis; 2000 Oct; 31(4):1110-3. PubMed ID: 11049800
[TBL] [Abstract][Full Text] [Related]
8. Long term failure of miltefosine in the treatment of refractory visceral leishmaniasis in AIDS patients.
Troya J; Casquero A; Refoyo E; Fernández-Guerrero ML; Górgolas M
Scand J Infect Dis; 2008; 40(1):78-80. PubMed ID: 17852921
[TBL] [Abstract][Full Text] [Related]
9. Oral miltefosine treatment in children with mild to moderate Indian visceral leishmaniasis.
Sundar S; Jha TK; Sindermann H; Junge K; Bachmann P; Berman J
Pediatr Infect Dis J; 2003 May; 22(5):434-8. PubMed ID: 12792385
[TBL] [Abstract][Full Text] [Related]
10. Leishmania infection can hamper immune recovery in virologically suppressed HIV-infected patients.
Gianotti N; Maillard M; Gaiera G; Bestetti A; Cernuschi M; De Bona A; Lazzarin A; Cinque P; Bossolasco S
New Microbiol; 2008 Jul; 31(3):435-8. PubMed ID: 18843901
[TBL] [Abstract][Full Text] [Related]
11. [Leishmaniasis--oral treatment with hexadecylphosphocholine].
Bommer W; Eibl HJ; Engel KR; Kuhlencord A; Sindermann H; Sundar S; Zappel H
Wien Klin Wochenschr; 2004; 116 Suppl 4():24-9. PubMed ID: 15683039
[TBL] [Abstract][Full Text] [Related]
12. Quantification of the response to miltefosine treatment for visceral leishmaniasis by QT-NASBA.
de Vries PJ; van der Meide WF; Godfried MH; Schallig HD; Dinant HJ; Faber WR
Trans R Soc Trop Med Hyg; 2006 Dec; 100(12):1183-6. PubMed ID: 16678871
[TBL] [Abstract][Full Text] [Related]
13. Efficacy of miltefosine for Bolivian cutaneous leishmaniasis.
Soto J; Rea J; Balderrama M; Toledo J; Soto P; Valda L; Berman JD
Am J Trop Med Hyg; 2008 Feb; 78(2):210-1. PubMed ID: 18256415
[TBL] [Abstract][Full Text] [Related]
14. Miltefosine as an effective choice in the treatment of post-kala-azar dermal leishmaniasis.
Ramesh V; Katara GK; Verma S; Salotra P
Br J Dermatol; 2011 Aug; 165(2):411-4. PubMed ID: 21561437
[TBL] [Abstract][Full Text] [Related]
15. Oral miltefosine for the treatment of Indian visceral leishmaniasis.
Sundar S; Jha TK; Thakur CP; Bhattacharya SK; Rai M
Trans R Soc Trop Med Hyg; 2006 Dec; 100 Suppl 1():S26-33. PubMed ID: 16730038
[TBL] [Abstract][Full Text] [Related]
16. Chronic cutaneous leishmaniasis in an immunocompetent patient: response to miltefosine.
Ruiz-Villaverde R; Sánchez-Cano D; Villaverde-Gutierrez C
J Eur Acad Dermatol Venereol; 2007 May; 21(5):695-6. PubMed ID: 17447994
[No Abstract] [Full Text] [Related]
17. Successful treatment of post-kala-azar dermal leishmaniasis (PKDL) in a HIV infected patient with multiple relapsing leishmaniasis from Western Europe.
Rihl M; Stoll M; Ulbricht K; Bange FC; Schmidt RE
J Infect; 2006 Jul; 53(1):e25-7. PubMed ID: 16274744
[TBL] [Abstract][Full Text] [Related]
18. Treatment of American cutaneous leishmaniasis with miltefosine, an oral agent.
Soto J; Toledo J; Gutierrez P; Nicholls RS; Padilla J; Engel J; Fischer C; Voss A; Berman J
Clin Infect Dis; 2001 Oct; 33(7):E57-61. PubMed ID: 11528586
[TBL] [Abstract][Full Text] [Related]
19. [Oral miltefosine to treat leishmaniasis].
Soto J; Soto P
Biomedica; 2006 Oct; 26 Suppl 1():207-17. PubMed ID: 17361856
[TBL] [Abstract][Full Text] [Related]
20. Treatment of New World cutaneous leishmaniasis with miltefosine.
Soto J; Berman J
Trans R Soc Trop Med Hyg; 2006 Dec; 100 Suppl 1():S34-40. PubMed ID: 16930649
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
